^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    BCMA-targeted CAR-T immunotherapy

    Related drugs:
    1d
    SLE-001: Descartes-08 for Patients With Systemic Lupus Erythematosus (clinicaltrials.gov)
    P2, N=6, Active, not recruiting, Cartesian Therapeutics | Trial completion date: Nov 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Descartes-08
    3d
    LTFU: Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (clinicaltrials.gov)
    P2/3, N=312, Recruiting, Celgene | N=214 --> 312
    Enrollment change
    |
    Breyanzi (lisocabtagene maraleucel) • Abecma (idecabtagene vicleucel)
    3d
    A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Suzhou Immunofoco Biotechnology Co., Ltd
    New P1/2 trial
    4d
    Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Cartesian Therapeutics | Trial completion date: Dec 2026 --> Dec 2028 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Descartes-08
    7d
    Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Washington University School of Medicine | Trial completion date: Jul 2028 --> Nov 2028 | Initiation date: Jan 2026 --> May 2026 | Trial primary completion date: Oct 2027 --> Feb 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    clonoSEQ
    |
    Carvykti (ciltacabtagene autoleucel) • Hyleukin-7 (efineptakin alfa)
    15d
    A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel (clinicaltrials.gov)
    P2, N=60, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jan 2028 --> Apr 2028
    Trial primary completion date
    |
    bortezomib • cyclophosphamide • Darzalex (daratumumab) • fludarabine IV • Carvykti (ciltacabtagene autoleucel)
    15d
    EPIC: Elranatamab in R/R Multiple Myeloma (clinicaltrials.gov)
    P2, N=32, Recruiting, Massachusetts General Hospital | Trial primary completion date: Dec 2025 --> Aug 2026
    Trial primary completion date
    |
    Elrexfio (elranatamab-bcmm) • Abecma (idecabtagene vicleucel)
    16d
    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4) (clinicaltrials.gov)
    P3, N=508, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting | Trial completion date: Apr 2029 --> Jul 2030
    Enrollment open • Trial completion date
    |
    bortezomib • Darzalex (daratumumab) • carfilzomib • dexamethasone • pomalidomide • AZD0120
    17d
    Lymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function (clinicaltrials.gov)
    P1, N=16, Recruiting, Washington University School of Medicine | N=12 --> 16 | Trial completion date: Mar 2027 --> May 2028 | Trial primary completion date: Apr 2026 --> Jun 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD34 (CD34 molecule)
    |
    clonoSEQ
    |
    cyclophosphamide • Carvykti (ciltacabtagene autoleucel)
    21d
    Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane CD28 domain. (PubMed, J Immunother Cancer)
    Incorporating a CD28-TMD into the ARI0002h CAR enhances tumor control even in relapse models with downregulation of the target antigen, offering improved long-term disease management. This modification increases potency against MM tumor cell lines with both normal and reduced BCMA expression, demonstrating superior metabolic endurance and in vivo activity.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    cesnicabtagene autoleucel (ARI0002h)
    23d
    KarMMa-9: A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (clinicaltrials.gov)
    P3, N=79, Active, not recruiting, Celgene | N=618 --> 79 | Trial completion date: Aug 2025 --> Nov 2029
    Enrollment change • Trial completion date
    |
    lenalidomide • cyclophosphamide • fludarabine IV • Abecma (idecabtagene vicleucel)
    23d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) (clinicaltrials.gov)
    P1, N=40, Recruiting, AstraZeneca | N=64 --> 40
    Enrollment change
    |
    AZD0120